Across TCGA pan-cancer cohorts, PXMP2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PXMP2’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PXMP2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PXMP2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.
CCRCC, LUAD, and COAD are the cancer types where PXMP2 tumor–normal differential expression is most reproducible.